Get the Stockscreener App
14.68
3.04%
-0.46
Gh Research Plc stock is traded at $14.68, with a volume of 74,985.
It is down -3.04% in the last 24 hours and down -7.85% over the past month.
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.
See More
Previous Close:
$15.14
Open:
$14.97
24h Volume:
74,985
Relative Volume:
0.22
Market Cap:
$910.59M
Revenue:
-
Net Income/Loss:
$-48.26M
P/E Ratio:
-18.58
EPS:
-0.7899
Net Cash Flow:
$-45.04M
1W Performance:
+4.41%
1M Performance:
-7.85%
6M Performance:
+12.15%
1Y Performance:
+57.51%
1-Day Range:
$14.33
$14.97
1-Week Range:
$14.04
$15.80
52-Week Range:
$7.98
$19.51
Gh Research Plc Stock (GHRS) Company Profile
Compare GHRS vs VRTX, REGN, ARGX, ALNY, INSM
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GHRS
Gh Research Plc
|
14.68 | 910.59M | 0 | -48.26M | -45.04M | -0.7899 |
VRTX
Vertex Pharmaceuticals Inc
|
431.86 | 109.85B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
760.27 | 80.38B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
765.43 | 47.60B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
319.52 | 42.63B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
163.03 | 35.19B | 606.42M | -1.28B | -997.58M | -6.403 |
Gh Research Plc Stock (GHRS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-13-25 | Initiated | Needham | Buy |
| Jun-04-25 | Resumed | Cantor Fitzgerald | Overweight |
| Mar-13-25 | Initiated | Guggenheim | Buy |
| Mar-07-25 | Initiated | RBC Capital Mkts | Outperform |
| Feb-13-25 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-16-22 | Initiated | H.C. Wainwright | Buy |
| Jun-16-22 | Initiated | ROTH Capital | Buy |
View All
Gh Research Plc Stock (GHRS) Latest News
Net current asset value per share of GH Research Plc – DUS:1KA - TradingView
GH Research (NASDAQ: GHRS) COO details multiple share option grants - stocktitan.net
GH Research PLC (GHRS) director details share and option holdings - stocktitan.net
GH Research (GHRS) executive details direct shares and option grants - stocktitan.net
GH Research (NASDAQ: GHRS) director details initial share and option positions - stocktitan.net
GH Research (NASDAQ: GHRS) CEO reports sizeable option grants and vesting - stocktitan.net
GH Research (GHRS) VP, Finance reports multiple option grants - stocktitan.net
GH Research (GHRS) director discloses 14.8M Ordinary Shares in Form 3 - stocktitan.net
GH Research (GHRS) price target increased by 18.94% to 40.04 - MSN
S P Trends: What are the risks of holding GH Research PLC2026 Market Mood & Risk Managed Investment Signals - baoquankhu1.vn
GH Research (NASDAQ:GHRS) Shares Gap DownShould You Sell? - MarketBeat
Discipline and Rules-Based Execution in GHRS Response - Stock Traders Daily
The 15-Minute Breakthrough: A Deep Dive into GH Research (GHRS) and the Future of Rapid-Acting Psychedelics - The Chronicle-Journal
Short Squeeze: What is the dividend yield of GH Research PLCTrade Volume Summary & Safe Capital Growth Stock Tips - baoquankhu1.vn
GH Research publishes phase 2b results for depression treatment By Investing.com - Investing.com Australia
GH Research Publishes Phase 2b GH001 TRD Data and Highlights Severity-Independent Efficacy - TipRanks
GH Research PLC (GHRS) stock: Clinical Trial Success Signals Potential Shift in Depression Treatment - parameter.io
GH Research publishes phase 2b results for depression treatment - Investing.com
GH Research PLC Announces Peer-Reviewed Publications of Phase 2b Results for GH001 in Treatment-Resistant Depression - Quiver Quantitative
GH Research (Nasdaq: GHRS) reports Phase 2b TRD results for GH001 - Stock Titan
GH Research Announces Publication of Phase 2b Results for Mebufotenin (GH001) in JAMA ... - Caledonian Record
GH Research Announces Publication of Phase 2b Results for - GlobeNewswire
Depression drug worked despite multiple prior treatment failures - Stock Titan
What Does GH Research PLC (GHRS)’s Clinical Progress Updates Say? - Insider Monkey
5 Best Psychedelic Stocks to Buy in 2026 - Insider Monkey
Aug Outlook: What is the dividend yield of GH Research PLCWeekly Stock Summary & Weekly Chart Analysis and Trade Guides - baoquankhu1.vn
GHRS PE Ratio & Valuation, Is GHRS Overvalued - Intellectia AI
GH Research PLC: Fundamental Analysis and Financial Ratings | | IE000GID8VI0 - marketscreener.com
Behavioral Patterns of GHRS and Institutional Flows - Stock Traders Daily
Buyout Rumor: Can GH Research PLC ride the EV wave2026 Top Decliners & High Accuracy Investment Entry Signals - baoquankhu1.vn
Growth Value: Can Embrace Change Acquisition Corp Equity Right maintain sales growthMarket Sentiment Summary & Stepwise Trade Signal Implementation - baoquankhu1.vn
GH Research PLC (NASDAQ:GHRS) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
GH Research to Join Stifel 2026 Virtual CNS Forum Fireside Chat - TipRanks
GH Research PLC (NASDAQ: GHRS) to join fireside chat at Stifel 2026 Virtual CNS Forum - Stock Titan
HighVista Strategies LLC Grows Stake in GH Research PLC $GHRS - MarketBeat
Analysts Set Expectations for GH Research Q1 Earnings - MarketBeat
Whale Trades: Is GH Research PLC stock undervalued right nowGap Up & Safe Swing Trade Setup Alerts - baoquankhu1.vn
GH Research FY25 Results: Strong Cash Position As GH001 Advances Toward Phase 3 - Seeking Alpha
Guggenheim raises GH Research stock price target to $34 on trial data - Investing.com Australia
Guggenheim raises GH Research stock price target to $34 on trial data By Investing.com - Investing.com India
GH Research reports Phase 2b trial results for depression treatment - Investing.com Nigeria
Activity Recap: Does GH Research PLC stock benefit from AI growthQuarterly Profit Report & Stepwise Swing Trade Plans - baoquankhu1.vn
Weekly Roundup on the Cannabis Sector & Psychedelic Sector - marketexclusive.com
(GHRS) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
Aug Ideas: Can GH Research PLC ride the EV waveJuly 2025 Closing Moves & Weekly Market Pulse Updates - baoquankhu1.vn
HC Wainwright Forecasts Reduced Earnings for GH Research - Defense World
Citizens raises GH Research stock price target on phase 3 progress - Investing.com India
GH Research (NASDAQ:GHRS) Stock Price Expected to Rise, Citizens Jmp Analyst Says - MarketBeat
Needham raises GH Research stock price target to $32 on phase 3 plans - Investing.com Australia
Needham raises GH Research stock price target to $32 on phase 3 plans By Investing.com - Investing.com South Africa
GH Research (NASDAQ:GHRS) Stock Price Expected to Rise, Needham & Company LLC Analyst Says - MarketBeat
Gh Research Plc Stock (GHRS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.47%
2.75%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):